Celltrion announced that they will embark on the approval procedure of biosimilar 'Remsima' in the United States
On June 2, Celltrion announced that they will embark on the approval procedure of biosimilar 'Remsima' in the United States.
According to Celltrion, they plan to submit permission application for sales in the U.S. based on the result of global phase 1, 3 clinical trial and result of clinical tri...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
